Tigecycline's Effects on Liver Enzymes
Tigecycline, a glycylcycline antibiotic used for complicated infections, can elevate liver enzymes in patients. Clinical trials and post-marketing data show it raises alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels, typically as mild to moderate increases that resolve after stopping the drug.[1][2]
Frequency and Severity in Studies
In phase 3 trials involving over 3,700 patients, liver enzyme elevations occurred in 15-25% of tigecycline-treated patients versus 10-20% on comparators. Severe cases (ALT/AST >10x upper limit of normal) affected about 1-2%, often in those with risk factors like prior liver disease or concurrent hepatotoxins. Elevations peak within 7-14 days of treatment and decline post-discontinuation.[2][3]
Risk Factors and Monitoring
Patients with hepatitis, alcohol use, or other liver stressors face higher risks. Labeling recommends baseline liver tests and monitoring every 3-5 days during 5-14 day courses. Discontinue if transaminases exceed 5-10x normal or symptoms like jaundice appear.[1][4]
Mechanism Behind Elevations
Tigecycline may cause direct hepatocyte toxicity or cholestasis via mitochondrial inhibition, though exact pathways remain unclear. Unlike tetracyclines, it shows less association with microvesicular steatosis.[3][5]
Reversibility and Long-Term Outcomes
Most elevations are asymptomatic and reversible within weeks. Rare cases progress to acute liver injury, with recovery in 90%+. No strong link to chronic liver damage in follow-up data.[2][6]
Comparisons to Other Antibiotics
Tigecycline's hepatotoxicity rate exceeds vancomycin (5-10%) but matches some cephalosporins. It's higher than doxycycline, prompting caution in short-term use.[3][7]
Sources
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: FDA Adverse Event Reporting System (FAERS) Summary
[3]: Hepatotoxicity of Antibiotics Review (LiverTox/NIH)
[4]: IDSA Guidelines on Tigecycline Use
[5]: Mechanisms of Glycylcycline Hepatotoxicity (PubMed)
[6]: Post-Marketing Surveillance Data (EMA)
[7]: Comparative Antibiotic Hepatotoxicity Meta-Analysis